Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.

Onco Targets Ther · 2016 · PMC5045229 · PMID 27713636

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with less change in PD-1 levels showed a trend to an improved PFS, and a decrease in myeloid-derived suppressor cells’ expression on treatment was associated with an improved PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.